Avelas Biosciences is a clinical-stage oncology company focused on developing AVB-620, a novel drug-device combination product for use during cancer surgery. AVB-620 helps improve surgery by detecting cancer in real-time and has the potential to become part of standard-of-care treatment for a variety of cancer surgeries.
Avelas is currently in a Phase II/III registration trial for the use of AVB-620 during breast cancer surgery.
May 19, 2020
Avelas and AxelaRx Announce Collaboration to Accelerate the Development of Promising Nerve Imaging AgentsRead more
Feb 26, 2020
Avelas Biosciences Voted Innovator of the Year at Field Service Medical 2020Read more
Nov 22, 2019
Avelas Welcomes Susan Stimson to its Board of DirectorsRead more